Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...
The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For 2025, competition and supply constraints are areas to watch.
Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...
Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to ...
Royal Caribbean is facing a lawsuit from a dozen passengers who claim they were filmed naked in their cabins while on the ...
Even the most iconic brand occasionally finds itself at a crossroads. A strong identity can keep you relevant for decades, ...
Study finds GLP-1 medications such as Ozempic could result in cuts to grocery spending and reductions in spending at ...
( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.
What a year! What do you think was the most important news in the United States in 2024? This list probably doesn’t reflect that. Rather, it shows what you, the readers, were looking at on ...
Worried about mental health effects of ozempic? Here's what recent studies reveal about safety concerns and what you should discuss with your doctor ...